Tenosynovial Giant Cell Tumor Treatment
Apr 03, 2026
Tenosynovial Giant Cell Tumor Treatment Landscape: A Dual-Modality Race Targeting CSF1R
Summary TGCT tumors are driven by a chromosomal translocation involving chromosomes 1 and 2, which results in overexpression of colony-stimulating factor-1 (CSF-1) and promotes tumor proliferation. Currently available systemic therapies, such as Daiichi Sankyo’s TURALIO and Ono Pharma’s ROMVIMZA, provide opt...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
